Testosterone research brings new hope for cancer patients

July 13, 2018 by Heather Gillin, Texas A&M University

Many cancer patients suffer from a loss of body mass known as cachexia. Approximately 20 percent of cancer related deaths are attributed to the syndrome of cachexia, which in cancer patients is often characterized by a rapid or severe loss of fat and skeletal muscle. Dr. Melinda Sheffield-Moore, professor and head of the Department of Health and Kinesiology, along with researchers at University of Texas Medical Branch, recently published research in the Journal of Cachexia, Sarcopenia and Muscle showing that the hormone testosterone is effective at combatting cachexia in cancer patients and improving quality of life.

These findings are important, as there are currently no established therapies targeting this loss of , and without an intervention, lose muscle function and become fatigued and weakened.

"We hoped to demonstrate these patients would go from not feeling well enough to even get out of bed to at least being able to have some basic quality of life that allows them to take care of themselves and receive therapy," Dr. Sheffield-Moore said.

Dr. Sheffield-Moore said doctors sought her expertise in nutrition and metabolism when patients were losing tremendous amounts of weight from cachexia. She said that previous nutrition-focused treatment failed to combat this severe loss of body mass, which led her team to investigate the as an option to combat the often debilitating consequences of cancer cachexia.

"We already know that testosterone builds skeletal muscle in healthy individuals, so we tried using it in a population at a high risk of muscle loss, so these patients could maintain their strength and performance status to be able to receive standard cancer therapies." Dr. Sheffield-Moore said.

During this five year National Cancer Institute funded study, patients with a type of cancer known as squamous cell carcinoma were treated with standard of care chemotherapy and/or radiation in addition to seven weeks of treatment with either testosterone or placebo. Throughout the study, patients were monitored for changes in physical activity, muscle and fat mass and tested for physical performance.

Patients in this study receiving testosterone maintained total body mass and increased lean body mass by 3.2 percent. Sustaining body mass is important considering most patients experience a 20 percent decrease in or more depending upon the type of cancer.

"Patients randomized to the group receiving testosterone as an adjuvant to their standard of care chemotherapy and/or radiation treatment also demonstrated enhanced physical activity," Dr. Sheffield-Moore said. "They felt well enough to get up and take care of some of their basic activities of daily living, like cooking, cleaning and bathing themselves."

Additionally, Dr. Sheffield-Moore's lab is currently analyzing skeletal muscle proteomic data from this study. "What the proteome [profile of proteins found in the ] tells us is which particular proteins in the skeletal muscles were either positively or negatively affected by testosterone or by cancer, respectively," Dr. Sheffield-Moore said. "It allows us to begin to dig into the potential mechanisms behind cancer cachexia."

Dr. Sheffield-Moore hopes this research will help increase quality of life and maintain eligibility to receive standard of care therapy if cachexia ensues.

Explore further: Excess zinc in muscles contributes to wasting syndrome in cancer

More information: Traver J. Wright et al, A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women, Journal of Cachexia, Sarcopenia and Muscle (2018). DOI: 10.1002/jcsm.12295

Related Stories

Excess zinc in muscles contributes to wasting syndrome in cancer

June 6, 2018
It's estimated that nearly one-third of all cancer deaths are caused not by the cancer itself but by cachexia—a debilitating muscle-wasting syndrome that affects an estimated 80 percent of advanced cancer patients. Cachexia ...

Muscle growth finding may assist with cancer treatment

June 13, 2017
Monash University's Biomedicine Discovery Institute (BDI) researchers have collaboratively developed a therapeutic approach that dramatically promotes the growth of muscle mass, which could potentially prevent muscle wasting ...

Heavy lifting for cancer research

February 9, 2012
Many patients with advanced cancer suffer from cachexia, a condition also called body-wasting or wasting syndrome, which causes significant weight loss, extreme fatigue and reduces quality of life.

Cancer wasting due in part to tumor factors that block muscle repair, study shows

October 23, 2013
A new study reveals that tumors release factors into the bloodstream that inhibit the repair of damaged muscle fibers, and that this contributes to muscle loss during cancer wasting. The condition, also called cancer cachexia, ...

Uncovering the genetics of skeletal muscle growth and regeneration

March 8, 2018
Skeletal muscle has a remarkable capacity to regenerate - a capacity that is diminished in many skeletal muscle diseases and aging. To investigate the mechanism behind skeletal muscle growth and regeneration, researchers ...

Brown fat found to be at the root of cancer-related wasting syndrome

July 17, 2014
Many patients with advanced stages of cancer, AIDS, tuberculosis, and other diseases die from a condition called cachexia, which is characterized as a "wasting" syndrome that causes extreme thinness with muscle weakness. ...

Recommended for you

Study finds melanoma biomarkers predicting checkpoint blocker response

July 18, 2018
Scientists at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood ...

Link found between bitter-taste sensitivity and cancer risk

July 18, 2018
High bitter-taste sensitivity is associated with a significantly increased risk of cancer in older British women, according to researchers who conducted a unique study of 5,500 women whose diet, lifestyle and health has been ...

Scientists discover a mechanism of drug resistance in breast and ovarian cancer

July 18, 2018
There is a highly sophisticated way to treat some breast and ovarian cancers—a class of drugs called PARP inhibitors, designed to exploit the very defects that make tumors with certain mutations especially deadly. Yet this ...

Research identifies new breast cancer therapeutic target

July 18, 2018
Research led by Suresh Alahari, Ph.D., Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, has shown for the first time that a tiny piece of RNA deregulates energy metabolism, an ...

Cancer patients may experience delayed skin effects of anti-PD-1 therapy

July 18, 2018
Cancer patients receiving anti-PD-1 therapies who develop lesions, eczema, psoriasis, or other forms of auto-immune diseases affecting the skin may experience those adverse reactions on a delay—sometimes even after treatment ...

Early supper associated with lower risk of breast and prostate cancer

July 18, 2018
Having an early supper or leaving an interval of at least two hours before going to bed are both associated with a lower risk of breast and prostate cancer. Specifically, people who take their evening meal before 9 p.m. or ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.